Suzuki Fronx With Level 2 ADAS Rolls Out In Indonesia; Is India Next?
The Suzuki Fronx gets either a 1.5-liter K15B petrol engine or a 1.5-liter K15C mild-hybrid petrol engine available in Indonesia. However, the India-spec Fronx gets a 1.2-litre K-series engine of the brand or a 1.0-litre K-series turbo petrol engine (available as an option). The transmission options include a 5-speed MT and a 5-speed AMT for the naturally aspirated engine, and a 5-speed MT along with a 6-speed AT for the turbo petrol.
The Suzuki Fronx has now been updated for the Indonesian market with Level 2 ADAS. It includes safety features like blind spot monitoring, Adaptive Cruise Control, Lane Keep Assist, Lane Departure Warning, Hill Hold Control, Electronic Stability Program, and much more. However, the Maruti Suzuki Fronx available in India does not get Level 2 ADAS currently, the brand is liklet to bring the update soon.
Suzuki Fronx Japan NCAP
The Fronx recently went for the Japan NCAP crash test, scoring 84 percent on the assessment. Specifically, it has managed to get an overall 163.75 points out of a total of 193.8 points. Apart from that, the car scored 79.42 points out of 85.8 points in the preventive safety performance test, while the collision safety performance test ended with a score of 76.33 points out of 100 points.
The Maruti Suzuki Fronx in India is sold at a starting price of Rs 7.54 lakh (ex-showroom) and goes up to Rs 12.90 lakh (ex-showroom).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
22 minutes ago
- Economic Times
Healthcare costs in US to shoot up following Trump tariff on Indian goods: Industry experts
Agencies Representative Image New Delhi: Healthcare costs in the US will increase following the imposition of sweeping 25 per cent tariff plus an unspecified penalty on Indian goods, experts from pharmaceuticals and medical devices industry said on Thursday. President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment. Profits for Indian pharmaceutical firms may decline and research and development may stagnate. However, for the medical devices sector as long as the gap between duty on China and India is over 15- 20 per cent, there are positive prospects for exports to the US, according to experts. "India isn't just a key supplier of generics to the US. We are a part of the backbone of affordable global healthcare. These duties may interrupt the smooth trade flow, inflate US drug costs, stall treatments, and put even greater pressure on American healthcare budgets," OmniActive Health Technologies Executive Chairman and MD Sanjaya Mariwala said. On the other hand, he said, "Back home, the profits for Indian pharmaceutical firms may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances." AiMeD (Association of Indian Medical Device Industry) Forum Coordinator Rajiv Nath said, "Duties impact for Indian medical devices sector has to be seen from relative competitiveness - as long as duty gap between Chinese versus Indian is over 15- 20 per cent, we have positive prospects to export to USA and even put production lines in USA." Currently Indonesia and Vietnam have lower duties by 6 per cent. So for products made there they will possibly enjoy a price competitive advantage over India, he added. Stating that clarity will come after August 12 as then duties on Chinese goods will be clear, Nath said, "They were increased to over 50 per cent but temporarily reduced to 30 per cent. If post-August duties on Chinese medical devices revert to over 50 per cent and on Indian at 25 per cent, the export prospects versus China are in our favour..." He further said, "Suffice to say that whatever is the final duty that is finally announced on medical devices, if it's at least 15-20 per cent lower than applicable duty rates by US onto China then there is a strong opportunity for Indian medical devices to increase their exports to US market, if they are able to absorb the excessive high cost of regulatory approval of USFDA for market entry and find that these costs to export are sustainable over the years." However, he said, the government of India and manufacturers will need to work to improve India's competitiveness "so that we can offset the 6 per cent disadvantage over Indonesian and Vietnam competitors". Grant Thornton Bharat Partner and Tax Controversy Management Leader Manoj Mishra pointed out that the strong language used by President Trump and ongoing investigations into drug imports mean that the risk is not over yet. "Indian pharma companies should stay prepared for possible changes, especially if sector-specific duties are introduced later. That said, these tariffs are likely to be in place only for a short period, as both countries are expected to fast-track discussions for a Bilateral Trade Agreement. A balanced and stable trade deal will be key to protecting long-term interests of the sector," he noted. Similarly, Choice Broking Equity Research Analyst- Pharma Sector, Maitri Sheth said the US remains heavily reliant on India for its pharmaceutical needs, with about 50 per cent of generic drugs sourced from India. "Given the critical nature of healthcare and already elevated healthcare costs in the US, we view the likelihood of material near-term tariffs on pharma as low," Sheth added. While the headline risk persists, the structural dependence on Indian pharma and the cost sensitivity of the US healthcare system provide a strong case against aggressive tariff action on the sector, Sheth added. Medical Technology Association of India (MTaI) Chairman Pavan Choudary said President Trump's is "troubling and seems economically shortsighted and strategically misguided".
Indian Express
4 hours ago
- Indian Express
Iveco deal: Here's how Tata Motors plans to fund the acquisition
Tata Motors on Thursday announced plans to raise around 1 billion euro (approximately $1.14 billion or Rs 10,000 crore) in equity to help repay the loan used for its 3.8 billion euro (Rs 38,000 crore) acquisition of Iveco's trucks and bus business. The company also hinted at the possibility of launching Iveco vehicles in India and Tata vehicles in markets where Iveco has a strong presence. The proposed acquisition — Tata Motors' largest since its $2.3 billion purchase of Jaguar Land Rover in 2008 — excludes Iveco's defence operations. It will be funded initially through a 3.8 billion euro bridge loan committed by Morgan Stanley and MUFG. Tata Motors aims to repay the debt over four years, using a mix of internal cash flows, proceeds from a potential 1 billion euro equity raise (via rights issue or QIP) and monetisation of its stake in Tata Capital. 'We plan to refinance the bridge loan with a mix of long-term debt and equity within 12 to 18 months after the deal closes,' PB Balaji, CFO of Tata Motors, said in a conference call. 'We are targeting to repay the entire acquisition debt over a four-year period.' Tata Motors expects the deal to be earnings accretive from the second year onwards, driven by cost synergies and the relatively low acquisition multiple. Tata Motors Executive Director Girish Wagh said the product portfolios of Tata Motors and Iveco complement each other in both pricing and capability. 'Iveco brings strong technology in areas like powertrain electrification, hydrogen and ADAS. Combined with our frugal engineering and design-to-value strengths, we see strong competitive advantages emerging,' Wagh said. He said revenue synergies could come from launching Iveco products in India and Tata vehicles in regions like Latin America where Iveco is established. However, he clarified that the Iveco brand, operations, and distribution channels would continue to operate independently post-acquisition. Tata Motors was in talks with Iveco for the last six months. Once completed, the acquisition will give Tata Motors access not only to new products, platforms, and manufacturing facilities but also to a well-established sales and after-sales network — not just in Europe, but also in Latin America, which typically takes years to build, noted Wagh. 'We'll also gain access to strong retail financing capabilities in several of these markets,' he said. Iveco has over 32,000 employees globally as of December 2024, excluding defence and discontinued operations.
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
Maruti Suzuki Q1 profit stays flat as exports rise 37% amid domestic slump
Carmaker posts Rs 3,792 crore profit in Q1 FY26 as exports to Japan and others rise 37%, softening the impact of a 4.5% domestic sales decline BS Reporter Chennai Maruti Suzuki India, the country's largest carmaker, posted a marginal 0.8 per cent increase in consolidated net profit to Rs 3,792.4 crore in the first quarter of FY2025-26, compared to Rs 3,759.7 crore a year earlier. A continued slump in small car sales and weak urban demand impacted domestic sales, but this was offset by a 37 per cent surge in exports. Total income for the April–June quarter rose 10 per cent year-on-year to Rs 40,493 crore from Rs 36,840 crore. Total vehicle sales stood at 527,861 units during the quarter, with domestic sales contributing 430,889 units and exports accounting for 96,972 units. Export performance outpaces industry trend 'The decline in domestic sales of around 4.5 per cent versus last year was compensated by a robust 37.4 per cent increase in exports, resulting in an overall sales volume increase of 1.1 per cent for the quarter,' said Rahul Bharti, senior executive director, corporate affairs, Maruti Suzuki India. While overall industry exports declined by 2.1 per cent, Maruti Suzuki's strong international performance—particularly in Japan—boosted the sector to a 13 per cent growth for the quarter. The company's export share rose to 47 per cent of total industry exports. Models like the Jimny and Fronx became popular overseas, especially in Japan, now the company's second-largest export market. 'We are exporting to around 100 countries now. A lot of efforts have gone in over the last decade at a structural level for building exports. We have improvised our network in quantity and quality. We have launched more products. We have carried examples of success from Indian markets to these areas,' Bharti said. SUVs and EVs on the horizon The company is planning to launch two new SUVs in the current fiscal year. While details were not confirmed, reports suggest one of the launches will be the e-Vitara—Maruti's entry into the electric vehicle segment—along with a possible seven-seater version of the Grand Vitara. On the issue of rare earth import dependency, especially from China, Bharti acknowledged the challenge but stated that the company's engineering teams are working on mitigation strategies. 'ICE vehicles also need [rare earths], but in a lesser quantity,' he noted. Awaiting clarity on CAFE norms Regarding the upcoming Corporate Average Fuel Efficiency (CAFE) norms, Bharti said a government decision is expected within a month or two, which would provide clarity on powertrain planning from April 1, 2027. Despite subdued Q1 results, the company remains optimistic about the second and third quarters. 'The industry was expecting 1–2 per cent growth. The first quarter has not been up to the mark, while Q2 has some positives like the monsoon, rural demand, and festive season. We are looking at Q2 and Q3 festive season with optimism,' Bharti said.
